cellvie is the leader in Therapeutic Mitochondria Transplantation (TMT).
The team is seeking to bring about a novel treatment modality, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell.
Therapeutic Mitochondria Transplantation, an approach for mitochondria augmentation and replacement, was developed by Dr. James McCully at Harvard Medical School. cellvie was founded to take this technology from bench to bed, starting in heart attacks and solid organ transplantation.
Company Details
- Employees
- 13
- Founded
- -
- Address
- Zuerich, Ch
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cellvie.bio
- Keywords
- Therapeutic Mitochondria Transfer, Mitochondria, Ischemia-Reperfusion Injury, Solid Organ Transplantation.
- HQ
- Zuerich
Cellvie Questions
Cellvie's website is cellvie.bio
Cellvie's LinkedIn profile is https://www.linkedin.com/company/cellvie
Cellvie has
13 employees.
View email and phone details for 13
employees at Cellvie.
Cellvie's industry is
Biotechnology Research
Cellvie's top competitors are
Herosupport Sa,
Innocent Meat,
Epiterna,
Longevity Center | Europe,
Haya Therapeutics,
Aeon,
Amazentis,
Ayun,
Amal Therapeutics,
Keen Wellbeing.
Cellvie's categories are Biotechnology Research
Cellvie's founding year is 2018
